AMENDMENTS TO THE CLAIMS:

Please amend the claims to read as shown below:

Claim 1 (Currently Amended) A method of diagnosis of stroke or the possibility thereof in a subject suspected of suffering from stroke, which comprises determining the concentration of at least one polypeptide selected from apolipoprotein (Apo) C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid obtained from the subject.

Claim 2 (Previously Presented) The method of claim 1, wherein the polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects, and the method includes determining whether the concentration of polypeptide in the sample is consistent with a diagnosis of stroke.

Claim 3 (Previously Presented) The method of claim 1, wherein an antibody to the polypeptide is used in determining of the concentration of the polypeptide.

Claim 4 (Previously Presented) The method of claim 1, wherein the body fluid is cerebrospinal fluid, plasma, serum, blood, tears or urine.

Claim 5 (Currently Amended) The method of claim 1, wherein the determination of the concentration of the polypeptide is used to determine whether a diagnosed stroke is of the ~~ischaemic or haemorrhagic~~ ischemic or hemorrhagic type.

Claim 6 (Previously Presented) The method of claim 1, further comprising subjecting a sample of body fluid obtained from the subject to mass spectrometry to determine a test amount of the polypeptide in the sample, wherein the polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects; and determining whether the test amount is consistent with a diagnosis of stroke.

Claim 7 (Previously Presented) The method of claim 1, wherein the polypeptide is present in the body fluid of stroke-affected subjects and not present in the body fluid of non-stroke-affected subjects, whereby the presence of the polypeptide in a body fluid sample is indicative of stroke.

Claim 8 (Previously Presented) The method of claim 1, wherein the polypeptide is not present in the body fluid of stroke-affected subjects and present in the body fluid of non-stroke-affected subjects, whereby the non-presence of the polypeptide in a body fluid sample is indicative of stroke.

Claim 9 (Previously Presented) The method of claim 6, wherein the mass spectrometry is laser desorption/ionization mass spectrometry.

Claim 10 (Currently Amended) The method of claim 6, wherein the sample is adsorbed on a probe having an ~~immobilised~~ immobilized metal affinity capture (IMAC), hydrophobic, strong anionic or weak cationic exchange surface capable of binding the polypeptide.

Claim 11 (Previously Presented) The method of claim 6, wherein the polypeptide is determined by surface-enhanced laser desorption/ionization (SELDI) and time of flight mass spectrometry (TOF-MS).

Claim 12 (Previously Presented) The method of claim 1, wherein a plurality of peptides is determined in the sample.

Claims 13 - 22 (Canceled)

Claim 23 (Withdrawn) An assay device for use in the diagnosis of stroke, which comprises a solid substrate having a location containing a material which recognizes, binds to or has affinity for a polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I.

Claim 24 (Withdrawn) The assay device of claim 23, wherein the solid substrate has plurality of locations each respectively containing a material which recognizes, binds to or has affinity for a polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I.

Claim 25 (Withdrawn) The assay device of claim 23, wherein the material is an antibody or antibody chip.

Claim 26 (Withdrawn) The assay device of claim 25, comprising a unique addressable location for each antibody, thereby to permit an assay readout for each individual polypeptide or for any combination of polypeptides.

Claim 27 (Withdrawn) The assay device of claim 25, wherein the antibody comprises an antibody to Apo C-III.

Claim 28 (Withdrawn) The assay device of claim 25, wherein the antibody comprises an antibody to Serum Amyloid A.

Claim 29 (Withdrawn) The assay device of claim 25, wherein the antibody comprises an antibody to Apo C-I.

Claim 30 (Withdrawn) The assay device of claim 25, wherein the antibody comprises an antibody to Antithrombin III.

Claim 31 (Withdrawn) The assay device of claim 25, wherein the antibody comprises an antibody to Apo A-I.

Claim 32 (Withdrawn) A kit for use in diagnosis of stroke, comprising a probe for receiving a sample of body fluid, and for placement in a mass spectrometer, thereby to determine a test amount of a polypeptide in the sample, wherein the polypeptide is selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I, or any combination thereof.

Claim 33 (Withdrawn) The kit of claim 32, wherein the probe contains an adsorbent for adsorption of the polypeptide.

Claim 34 (Withdrawn) The kit of claim 33, further comprising a washing solution for removal of unbound or weakly bound materials from the probe.